Results 111 to 120 of about 24,071 (243)

One-Month Real-World Comparison of Aflibercept 8 mg Versus 2 mg in Treatment-Naïve and Previously Treated Eyes with Neovascular Age-Related Macular Degeneration

Biologics
Background/Objectives: The relative efficacy of 8 mg aflibercept compared to 2 mg in treating neovascular age-related macular degeneration (nAMD) has not been fully established. This study aims to compare the visual and anatomical outcomes of aflibercept
Takahiro Mizukami, Satoru Ueno, Soichiro Mishima, Yoshikazu Shimomura   +3 more
doaj   +1 more source

Pharmacoeconomic analysis of anti-angiogenic therapy for diabetic macular edema

Качественная клиническая практика, 2019
Te purpose of the study is to assess the economic consequences of the use of various anti-VEGF drugs in patients with diabetic macular edema (DME).Materials and methods.
S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. O. Smirnova, E. A. Popova   +4 more
doaj   +1 more source

Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial [PDF]

, 2019
Francesco Semeraro, Elena Gambicordi, Anna Cancarini, Francesco Morescalchi, Ciro Costagliola, Andrea Russo   +5 more
openalex   +1 more source

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy [PDF]

, 2022
Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri   +3 more
openalex   +1 more source

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

American Journal of Ophthalmology Case Reports
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty, Ashish Sharma, Soumen Mondal, Jay Sheth, Tushar Kanti Sinha, Subhendu Boral, Angshuman Mukherjee, Ranabir Bhattacharya, Ritobroto Maitra   +8 more
doaj   +1 more source

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Clinical Ophthalmology, 2021
Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West ...
Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R   +6 more
doaj  

Targeted Therapies for Ovarian Cancer [PDF]

, 2016
Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies. Most women present with advanced disease and develop a recurrence after radical surgery and chemotherapy.
Grunewald, T, Ledermann, JA
core  

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept [PDF]

, 2014
Claudia Leteneux, J. Haig, Weiguang Xue, S. Bhattacharyya   +3 more
openalex   +1 more source

Practical implementation of a q4–q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel [PDF]

, 2022
Clare Bailey, Peter Cackett, Ajay Kotagiri, Sajjad Mahmood, Evangelos Minos, Nirodhini Narendran, Ashish Patwardhan, Dawn A. Sim, Peter Morgan-Warren, Carolyn O’Neil, Katie Straw   +10 more
openalex   +1 more source